相关实验视频

Updated: Feb 22, 2026

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Published on: November 8, 2024

芬太尼和西拉试验条的分析性能和视觉评估

Alan H B Wu¹, Chui Mei Ong², Melissa Alamillo²

¹Department of Laboratory Medicine, University of California, San Francisco, USA. alan.wu@ucsf.edu.

Harm reduction journal

|February 20, 2026

概括

芬太尼和西拉试验条的灵敏度和特异性各不相同. 一条西拉条 (上海精确诊断) 和一条芬太尼 (W.P.H.M.) 在药物伪造剂测试中获得最佳分析性能.

科学领域:

药物分析药物分析
法医毒理学法医毒理学
公共卫生公共卫生

背景情况:

在街上用芬太尼和西拉伪造药物存在重大风险.
药物测试条为用户提供评估药物安全性的手段.
有限的数据存在于商业上可用的测试条的现实世界性能.

研究的目的:

评估商业上可用的芬太尼和西拉试验条的分析灵敏度和特异性.
为了确定检测芬太尼和克西拉杂物中最敏感和最具特异性的试验条.

主要方法:

购买了三条西拉和三条芬太尼试验条.
使用芬太尼,西拉和模拟标准的连续稀释来评估分析灵敏度.
与常见的芬太尼类似物相比,评估了芬太尼条带的特异性.
在不同的照明条件下评估条纹性能.

主要成果:

所有的克西拉条都检测到药物低于规定的限值;一个显著更敏感 (50 ng/mL).
一个芬太尼条显示出高于其声明的限值 (20 ng/mL) 的灵敏度 (3.5 ng/mL).
芬太尼条带与类似物交叉反应,具有不同程度的特异性;所有这些都在弱光下表现不佳.

结论:

精选的上海精准诊断公司的西拉条和W.P.H.M. 基于优越的分析灵敏度的芬太尼条.
推用于检测芬太尼和西拉的特定试验条,承认特异性和低光条件的限制.

关键词:

芬太尼尔 (Fentanyl) 是一种药物.芬太尼的类似物芬太尼的类似物减少伤害减少伤害克西拉的伪造剂

更多相关视频

Development of a Lateral Flow Immunochromatographic Strip for Rapid and Quantitative Detection of Small Molecule Compounds

Development of a Lateral Flow Immunochromatographic Strip for Rapid and Quantitative Detection of Small Molecule Compounds

Published on: November 13, 2021

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Published on: February 5, 2018

相关概念视频

Drug Product Performance: In Vitro–In Vivo Correlation

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...